Gem Aromatics Ltd
Gem Aromatics Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #34 of 68 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
3 of 4 strong
The short version
Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum. FY27 is viewed as a ramp-up year with progressive commercialization of new product verticals (cooling agents, phenol derivatives, specialty aroma chemicals).
From Gem Aromatics Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum.
- New product verticals (cooling agents, Citral, Safranal, phenol derivatives) expected to contribute meaningful revenue starting Q2 to Q4 FY27.
- Cooling agents revenue will ramp up significantly by Q3 FY27 with initial orders secured and customer approvals ongoing.
- Phenol derivatives trial productions begin end-Q2 FY27; commercial production and meaningful revenue expected Q3 to Q4 FY27.
- Expansion of export markets, especially Western Hemisphere (U.S., Latin America), expected to drive volume growth.
- Scale-up of Dahej facility and Krystal Ingredients’ products to progressively increase revenue contribution through FY27 and materially in FY28.
2 more points from Gem Aromatics Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Gem Aromatics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The Dahej facility under Krystal Ingredients Private Limited has seen substantial capital investment with approximately INR270 crores capex, of which nearly INR265 crores have been incurred and capitalized.
- The company is progressing commercialization at Dahej, focusing on scaling new product verticals like cooling agents, phenol derivatives, and specialty aroma chemicals.
- There is a strong R&D pipeline developing new aroma chemical products targeting higher-value specialty molecules.
- Gem Aromatics has approved the incorporation of a Brazil subsidiary to expand distribution reach in Latin America, indicating strategic investment in international market presence.
2 more points from Gem Aromatics Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Gem Aromatics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Meaningful revenue from these products is expected by Q3 FY ‘27.
- The company has a large pipeline of new aroma chemical products in various stages of approval and execution.
- Approvals for newer products such as cooling agents, Citral derivatives, and phenol derivatives are progressing, with commercial revenues expected from Q2 to Q4 FY ‘27.
2 more points from Gem Aromatics Ltd's call on order book
Create a free account to keep reading this call
Gem Aromatics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹104 Cr, net loss ₹7 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Gem Aromatics's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Alufluoride (Q1 FY27)
Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr
- POCL Enterprises (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
- Devson Catalyst (Q1 FY27)
FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee
- Ambani Orgochem (Q1 FY27)
Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Gem Aromatics Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Gem Aromatics Ltd Q1 FY27 results?
Q1 FY27 showed YoY revenue growth despite seasonal softness, indicating positive momentum. FY27 is viewed as a ramp-up year with progressive commercialization of new product verticals (cooling agents, phenol derivatives, specialty aroma chemicals).
What is Gem Aromatics Ltd share price analysis?
Gem Aromatics Ltd currently shows a below-average growth signal. The stock trades at a P/E of 678.7 with a market cap of ₹964 Cr. Investors should review the full earnings analysis for detailed insights.
Is Gem Aromatics Ltd planning capital expenditure?
The Dahej facility under Krystal Ingredients Private Limited has seen substantial capital investment with approximately INR270 crores capex, of which nearly INR265 crores have been incurred and capitalized.
Keep Gem Aromatics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.